This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study (CD4-01)

This study has been completed.
Roche Pharma AG
Information provided by (Responsible Party):
University Hospital, Ghent Identifier:
First received: May 7, 2009
Last updated: October 12, 2016
Last verified: October 2016
This study is an open, randomised trial in which one group of patients (control) will receive the golden standard therapy and the other group (treatment) will receive individually adapted immunosuppression.

Condition Intervention Phase
Kidney Transplantation Drug: individual adapted immunosuppression Drug: golden standard therapy Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study

Resource links provided by NLM:

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Graft function as measured by Cr EDTA AUC [ Time Frame: at 1 year ]

Secondary Outcome Measures:
  • Graft survival [ Time Frame: at 1 year ]
  • Patient survival [ Time Frame: at 1 year ]
  • Graft function measured by estimated GFR (eGFR) (MDRD and Cockroft-Gault) [ Time Frame: at 1 year ]
  • Frequency of biopsy proven acute rejection episodes [ Time Frame: at 1 year ]
  • Incidence of biopsy proven acute rejection (BPAR) and clinical (non-biopsy proven) acute rejection episodes treated by a full course anti-rejection therapy (e.g. steroids) (Treatment of rejection according to center practice). [ Time Frame: at 1 year ]
  • Incidence of rejection treated by antibodies (OKT3, ATG) [ Time Frame: at 1 year ]
  • Time to first rejection (days) [ Time Frame: at 1 year ]
  • Severity of rejection as assessed by BANFF 2005 score [ Time Frame: at 1 year ]
  • Number of acute rejections per patient [ Time Frame: at 1 year ]
  • Plasma creatinine and eGFR [ Time Frame: at month 1, 3 and yearly (2 and 3 years) ]
  • Measured GFR [ Time Frame: at month 3 and yearly ]
  • Proteinuria [ Time Frame: at month 1, 3 and at 1 and 3 years ]
  • Incidence and score of borderline changes and acute rejection [ Time Frame: in month 3 and month 12 biopsy ]
  • Incidence and score of chronic alloimmune injury/rejection and nonimmune injury [ Time Frame: in month 3 and month 12 biopsies (BANFF 2005) ]
  • Development and evolution of glucose abnormalities [ Time Frame: at 1 year ]
  • blood pressure [ Time Frame: at 1 year ]
  • ambulatory 24-hr blood pressure monitoring [ Time Frame: at 1 year and 3 years ]
  • Left ventricular mass assessed by echocardiography [ Time Frame: at 1 year and 3 years ]
  • Fasting lipid profile [ Time Frame: at baseline, month 1,3,6 and yearly ]
  • CMV infection (as measured with whole blood PCR) and disease [ Time Frame: at 1 year ]
  • Polyoma virus replication as measured by whole blood PCR [ Time Frame: at 1 year ]
  • Incidence of BK nephritis [ Time Frame: in month 3 and month 12 biopsies ]
  • Incidence of PTLD and Nonmelanoma skin cancer [ Time Frame: at 1 year and yearly ]
  • Incidence of EBV reactivation (as measured with whole blood PCR) [ Time Frame: at 1 year and yearly ]

Enrollment: 128
Study Start Date: May 2009
Study Completion Date: October 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
individual adapted immunosuppression
Drug: individual adapted immunosuppression
individual adapted immunosuppression
Active Comparator: 2
golden standard therapy
Drug: golden standard therapy
golden standard therapy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First or second kidney transplantation
  • Males and females, 18 years old or older
  • Women of childbearing potential must have a negative serum or urine pregnancy test with sensitivity equal to at least 50 mIU/mL
  • Patients must be capable of understanding the purpose and risks of the study and must sign an informed consent form

Exclusion Criteria:

  • Multiple organ transplantation (eg. kidney-pancreas, kidney-heart, kidney-liver,...)
  • Transplantation of a patient who received another organ transplant previously except one kidney transplant
  • Recipients of HLA-identical living-related renal transplants
  • Patients with PRA > 10%, patients who have lost a first graft from rejection.
  • Pregnant or lactating women
  • WBC =< 2.5 x 109/L (IU), platelet count =< 100 x 109/L (IU), or Hb =< 6g/dl at the time of entry into the study
  • Active peptic ulcer
  • Severe diarrhea or other gastrointestinal disorders which might interfere with the ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy
  • Known HIV-1 or HTLV-1 positive tests
  • History of malignancy in the past 5 years (with the exception of adequately treated basal or squamous skin cell carcinoma)
  • The use of investigational drugs or other immunosuppressive drugs as those specified in this protocol
  • Patients receiving bile acid sequestrants
  • Psychological illness or condition interfering with the patient's compliance or ability to understand the requirements of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00895206

University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Roche Pharma AG
Principal Investigator: Raymond Vanholder, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: University Hospital, Ghent Identifier: NCT00895206     History of Changes
Other Study ID Numbers: 2008/640
Study First Received: May 7, 2009
Last Updated: October 12, 2016 processed this record on June 23, 2017